- Home
- LAZ vs RNA Comparison
LAZ vs RNA Comparison
Compare LAZ & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZ
- RNA
- Stock Information
- Founded
- LAZ 1848
- RNA 2012
- Country
- LAZ United States
- RNA United States
- Employees
- LAZ N/A
- RNA N/A
- Industry
- LAZ Investment Managers
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- LAZ Finance
- RNA Health Care
- Exchange
- LAZ Nasdaq
- RNA Nasdaq
- Market Cap
- LAZ 4.0B
- RNA 3.6B
- IPO Year
- LAZ 2005
- RNA 2020
- Fundamental
- Price
- LAZ $49.90
- RNA $29.11
- Analyst Decision
- LAZ Hold
- RNA Strong Buy
- Analyst Count
- LAZ 7
- RNA 14
- Target Price
- LAZ $46.33
- RNA $68.00
- AVG Volume (30 Days)
- LAZ 909.4K
- RNA 1.4M
- Earning Date
- LAZ 07-24-2025
- RNA 08-08-2025
- Dividend Yield
- LAZ 4.01%
- RNA N/A
- EPS Growth
- LAZ N/A
- RNA N/A
- EPS
- LAZ 2.87
- RNA N/A
- Revenue
- LAZ $2,939,019,000.00
- RNA $8,927,000.00
- Revenue This Year
- LAZ N/A
- RNA N/A
- Revenue Next Year
- LAZ $14.45
- RNA $156.80
- P/E Ratio
- LAZ $17.35
- RNA N/A
- Revenue Growth
- LAZ 7.18
- RNA N/A
- 52 Week Low
- LAZ $31.97
- RNA $21.51
- 52 Week High
- LAZ $61.14
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- LAZ 69.49
- RNA 44.16
- Support Level
- LAZ $47.40
- RNA $27.98
- Resistance Level
- LAZ $50.96
- RNA $29.70
- Average True Range (ATR)
- LAZ 1.30
- RNA 1.27
- MACD
- LAZ 0.42
- RNA -0.12
- Stochastic Oscillator
- LAZ 86.82
- RNA 39.44
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.